Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Candida Clear all
Completed Not applicable Interventional

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

NCT00005921
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
L-743,872
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rahway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 4 Interventional

Fluconazole Prophylaxis of Thrush in AIDS

NCT00001542
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions
fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 1:03 PM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 20, 2026, 1:03 PM EDT
Completed No phase listed Observational

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

NCT00721487
View directory record Official record
Conditions
Fungal Infection by Site
Interventions
Fluconazole
Drug
Lead sponsor
CPL Associates
Other
Eligibility
4 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

NCT00058682
View directory record Official record
Conditions
Candida, Candidiasis
Interventions
Anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

NCT03930745
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Placebo, TOL-463
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 20, 2026, 1:03 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of Candida Fungemia

NCT03827330
View directory record Official record
Conditions
Candida Fungemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 1:03 PM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

NCT01273922
View directory record Official record
Conditions
Staphylococcal Infections, Candidiasis
Interventions
NDV-3 investigational vaccine
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Candin for the Treatment of Common Warts

NCT05889845
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Candin, Intradermal Solution, Placebo
Drug
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fort Smith, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

NCT06146504
View directory record Official record
Conditions
Candida Systemic, Candida Albicans Infection, Candida Infection
Interventions
CanXida Remove (Formula RMV), Placebo
Dietary Supplement · Other
Lead sponsor
CanXida
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 20, 2026, 1:03 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

NCT01752166
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 20, 2026, 1:03 PM EDT
Recruiting Phase 2 Interventional

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

NCT05952934
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Biological · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

NCT00001280
View directory record Official record
Conditions
Mycoses
Interventions
itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

NCT00818584
View directory record Official record
Conditions
Candida
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
48 Hours to 120 Days
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

NCT00702507
View directory record Official record
Conditions
Diaper Rash
Interventions
0.25 % Miconazole Nitrate Ointment
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
Up to 15 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 20, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

NCT00815516
View directory record Official record
Conditions
Candidiasis
Interventions
micafungin, amphotericin B deoxycholate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
48 Hours to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Orange, California • New Brunswick, New Jersey • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

NCT00734539
View directory record Official record
Conditions
Candidiasis
Interventions
fluconazole, placebo
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
2 Days to 5 Days
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study

NCT05614726
View directory record Official record
Conditions
Microbiota, Constipation, Candida
Interventions
575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase
Dietary Supplement
Lead sponsor
The Center for Applied Health Sciences, LLC
Industry
Eligibility
30 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 20, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 1:03 PM EDT